Randomized Trial of C5a Receptor Inhibitor Avacopan in ANCA-Associated VasculitisDavid Jayne, Annette Bruchfeld, Lorraine Harper et al.|Journal of the American Society of Nephrology|2017Cited by 599
Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trialBrad H. Rovin, Catarina Almeida, Jula K. Inrig et al.|The Lancet|2023Cited by 264
KDIGO 2024 Clinical Practice Guideline for the Management of Antineutrophil Cytoplasmic Antibody (ANCA)–Associated VasculitisJürgen Floege, Brad H. Rovin, David Jayne et al.|Kidney International|2024Cited by 170
Characteristics and Outcomes of Granulomatosis With Polyangiitis (Wegener) and Microscopic Polyangiitis Requiring Renal Replacement Therapy: Results From the European Renal Association–European Dialysis and Transplant Association RegistryZdenka Hrušková, Kitty J. Jager, Vianda S Stel et al.|American Journal of Kidney Diseases|2015Cited by 62
Induction and maintenance of remission with mycophenolate mofetil in ANCA-associated vasculitis: a systematic review and meta-analysisAlvise Berti, Andreas Kronbichler, Mouaz Alsawas et al.|Nephrology Dialysis Transplantation|2021Cited by 26